GlaxoSmithKlineThe Impact of Medicines: Sustainability in Environment, Health and Safety Report 2002
Reporting Front PageDownloads
EHS 2002 home

About this report

Executive statements

Framework

EHS and EHM vision

Environment, health and safety policy

Planning

Organisation
CEHS
EHM
Partnerships

Management systems

Programmes

Audit

Stakeholder communication

Reward and recognition

Issues

Performance

Verification statement

Index

Organisation
Previous
Next
 
 

GlaxoSmithKline has several groups that identify governance and ethical issues, recommend ways to manage them and periodically review the management of the issues. EHS issues are among those reviewed and addressed by these groups.

The Risk Oversight and Compliance Council (ROCC) is responsible for co-ordinating the internal control and risk management activities of the company. EHS is identified as one of the areas of the business that has the potential for serious adverse consequences if not managed properly. The Vice President, Corporate Environment, Health and Safety is a member of ROCC. The ROCC reports its evaluation of EHS risk management to the Corporate Executive Team.

Ed Kaufman "GSK's ethical culture invigorates the approach to compliance across the business. The company manages risks to meet its own aspirations as well as to comply with external requirements. The high priority placed on EHS risks at GSK reflects a concern for the environment, employees and the wider community; it is also good for our business. I fully support GSK's formal process for managing EHS, which is based on global policies and standards and takes a management system approach." Ed Kaufman, MD, Vice President, Corporate Ethics and Compliance

The Corporate Executive Team (CET) actively manages EHS issues. JP Garnier has identified himself as the champion of environment, health and safety for both the CET and the Board. He ensures that EHS issues are regularly debated to verify that we are pursuing responsible programmes for all GSK operations.

The Board of Directors has two committees that evaluate the management and effectiveness of our EHS programme. These review and oversight mechanisms provide opportunities for environment, health and safety issues to be considered at the highest level of the organisation.

The Audit Committee of the Board reviews EHS performance to confirm that issues are properly managed and controlled. The Vice President, Corporate Environment, Health and Safety makes regular presentations to the Audit Committee so that they can review measures of environment, health and safety performance and track our progress toward meeting EHS targets. They also review the results of EHS audits of GSK operations, contract manufacturers and key suppliers. The level of scrutiny of the Audit Committee is in line with requirements of Sarbanes-Oxley.

The Corporate Social Responsibility Committee (CSRC) advises the Board on social, ethical and environmental issues that have the potential to seriously impact GSK's business and reputation. The Vice President, Corporate Environment, Health and Safety provides reports to the CSRC on those aspects of EHS that have social implications above strict regulatory compliance such as sustainability.



Previous

Next


Top


EHS 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated July 21, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement